D Shatin

Summary

Affiliation: United Behavioral Health
Country: USA

Publications

  1. ncbi Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants
    Deborah Shatin
    Center for Health Care Policy and Evaluation, UnitedHealth Group, Minneapolis, MN 55344, USA
    Pharmacoepidemiol Drug Saf 14:149-54. 2005
  2. ncbi Organizational context and taxonomy of health care databases
    D Shatin
    Center for Health Care Policy and Evaluation, UnitedHealth Group, MN008 W109, 9900 Bren Road East, Minnetonka, MN 55343, USA
    Pharmacoepidemiol Drug Saf 10:367-71. 2001
  3. ncbi Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization
    Deborah Shatin
    Center for Health Care Policy and Evaluation, UnitedHealth Group, Minnetonka, MN 55343, USA
    Ambul Pediatr 2:111-9. 2002
  4. ncbi Population-based hepatitis C surveillance and treatment in a national managed care organization
    Deborah Shatin
    UnitedHealth Group, Center for Health Care Policy and Evaluation, 12125 Technology Drive, MN002 0260, Minneapolis, MN 55344, USA
    Am J Manag Care 10:250-6. 2004
  5. ncbi Healthy pregnancy program in a national managed care organization: evaluation of satisfaction and health behavior outcomes
    C R Drinkard
    UnitedHealth Group, Center for Health Care Policy and Evaluation, 9900 Bren Road East, Mail Route MN008 W109, Minnetonka, MN 55343, USA
    Am J Manag Care 7:377-86. 2001
  6. ncbi Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations
    C R Drinkard
    Center for Health Care Policy and Evaluation, United Health Group, Minneapolis, MN, USA
    Pharmacoepidemiol Drug Saf 9:549-56. 2000
  7. ncbi Adverse events associated with prolonged antibiotic use
    Sharon B Meropol
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Pharmacoepidemiol Drug Saf 17:523-32. 2008
  8. ncbi The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D 24-Hour--original formulation)
    Bharati Manda
    Center for Health Care Policy and Evaluation, UnitedHealth Group, 12125 Technology Drive, MN002 0260, Minneapolis, MN 55344 7302, USA
    Pharmacoepidemiol Drug Saf 13:29-34. 2004
  9. ncbi Risk factors for statin-associated rhabdomyolysis
    Stephanie Schech
    Center for Health Care Policy and Evaluation, Eden Prairie, MN 55344, USA
    Pharmacoepidemiol Drug Saf 16:352-8. 2007
  10. ncbi Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    David J Graham
    Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    JAMA 292:2585-90. 2004

Detail Information

Publications19

  1. ncbi Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants
    Deborah Shatin
    Center for Health Care Policy and Evaluation, UnitedHealth Group, Minneapolis, MN 55344, USA
    Pharmacoepidemiol Drug Saf 14:149-54. 2005
    ....
  2. ncbi Organizational context and taxonomy of health care databases
    D Shatin
    Center for Health Care Policy and Evaluation, UnitedHealth Group, MN008 W109, 9900 Bren Road East, Minnetonka, MN 55343, USA
    Pharmacoepidemiol Drug Saf 10:367-71. 2001
    ..Coverage considerations that affect pharmacoepidemiologic research include eligibility, the nature of the pharmacy benefit, and regulatory aspects of the treatment under consideration...
  3. ncbi Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization
    Deborah Shatin
    Center for Health Care Policy and Evaluation, UnitedHealth Group, Minnetonka, MN 55343, USA
    Ambul Pediatr 2:111-9. 2002
    ..To provide a description of the ambulatory use of psychotropic medications by children and adolescents in a large, geographically diverse employer-insured population...
  4. ncbi Population-based hepatitis C surveillance and treatment in a national managed care organization
    Deborah Shatin
    UnitedHealth Group, Center for Health Care Policy and Evaluation, 12125 Technology Drive, MN002 0260, Minneapolis, MN 55344, USA
    Am J Manag Care 10:250-6. 2004
    ..To use a national population-based automated claims database to study the testing rate, prevalence, and prescribing patterns for chronic hepatitis C...
  5. ncbi Healthy pregnancy program in a national managed care organization: evaluation of satisfaction and health behavior outcomes
    C R Drinkard
    UnitedHealth Group, Center for Health Care Policy and Evaluation, 9900 Bren Road East, Mail Route MN008 W109, Minnetonka, MN 55343, USA
    Am J Manag Care 7:377-86. 2001
    ..To evaluate satisfaction with the Healthy Pregnancy Program (HPP), which was developed to educate and coordinate the care of pregnant women in a managed care setting...
  6. ncbi Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations
    C R Drinkard
    Center for Health Care Policy and Evaluation, United Health Group, Minneapolis, MN, USA
    Pharmacoepidemiol Drug Saf 9:549-56. 2000
    ....
  7. ncbi Adverse events associated with prolonged antibiotic use
    Sharon B Meropol
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Pharmacoepidemiol Drug Saf 17:523-32. 2008
    ....
  8. ncbi The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D 24-Hour--original formulation)
    Bharati Manda
    Center for Health Care Policy and Evaluation, UnitedHealth Group, 12125 Technology Drive, MN002 0260, Minneapolis, MN 55344 7302, USA
    Pharmacoepidemiol Drug Saf 13:29-34. 2004
    ....
  9. ncbi Risk factors for statin-associated rhabdomyolysis
    Stephanie Schech
    Center for Health Care Policy and Evaluation, Eden Prairie, MN 55344, USA
    Pharmacoepidemiol Drug Saf 16:352-8. 2007
    ..To identify and characterize risk factors for rhabdomyolysis in patients prescribed statin monotherapy or statin plus fibrate therapy...
  10. ncbi Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    David J Graham
    Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    JAMA 292:2585-90. 2004
    ..Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available...
  11. ncbi New-onset and idiopathic thrombotic thrombocytopenic purpura: incidence, diagnostic validity, and potential risk factors
    Stephanie D Schech
    Center for Health Care Policy and Evaluation, Eden Prairie, MN 55344, USA
    Am J Hematol 81:657-63. 2006
    ..The aim of this study was to determine the incidence rate for new-onset and idiopathic thrombotic thrombocytopenic purpura (TTP) among adults 20-64 years old, the validity of diagnostic criteria, and potential risk factors for TTP...
  12. ncbi Perinatal hepatitis B transmission and vaccination timing in a managed care cohort: assessment of the temporary delay in newborn hepatitis B vaccination due to thimerosal content
    Soju Chang
    Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Rockville, MD 20852, USA
    Pediatr Infect Dis J 26:329-33. 2007
    ..S. childhood immunization schedule, of vaccinations during the first 2 years of life...
  13. ncbi Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists
    Jeffrey R Curtis
    University of Alabama at Birmingham, Center for Education and Research on Therapeutics, AL 35294, USA
    Arthritis Rheum 56:1125-33. 2007
    ..To evaluate the risk of serious bacterial infections associated with tumor necrosis factor alpha (TNFalpha) antagonists among rheumatoid arthritis (RA) patients...
  14. ncbi Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions
    Deborah Shatin
    Center for Health Care Policy and Evaluation, Minneapolis, MN, USA
    Pharmacoepidemiol Drug Saf 15:11-8. 2006
    ..We also found variation in the tuberculin skin testing rate associated with physician specialty. This study demonstrates a significant change in patient care following risk communication efforts...
  15. ncbi Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis
    Susan E Andrade
    Meyers Primary Care Institute Fallon Foundation and University of Massachusetts Medical School, 630 Plantation Street, Worcester, MA 01605, USA
    J Clin Epidemiol 58:171-4. 2005
    ....
  16. ncbi Pharmacy data for tuberculosis surveillance and assessment of patient management
    Deborah S Yokoe
    Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Emerg Infect Dis 10:1426-31. 2004
    ..Pharmacy data can help public health officials to find TB cases and assess their management in populations that receive care in the private sector...
  17. ncbi A study of compliance with FDA recommendations for pemoline (Cylert)
    Mary E Willy
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    J Am Acad Child Adolesc Psychiatry 41:785-90. 2002
    ..CONCLUSIONS: Compliance with product labeling was low for both recommendations. Understanding the reasons for this finding could help improve risk management strategies...
  18. ncbi Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone
    David J Graham
    Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Am J Gastroenterol 98:175-9. 2003
    ..3, 1385). CONCLUSIONS: Troglitazone use was associated with a marked increase in risk of hospitalized acute idiopathic liver injury and ALF...
  19. ncbi Ambulatory use of ticlopidine and clopidogrel in association with percutaneous coronary revascularization procedures in a national managed care organization
    Deborah Shatin
    Center for Health Care Policy and Evaluation, MN008-W109, UnitedHealth Group, 9900 Bren Rd. East, Minnetonka, MN 55343, USA
    J Interv Cardiol 15:181-6. 2002
    ..These results were important in considering the overall benefit-risk profile...